AFT Pharmaceuticals - Another R&D asset in the bag
AFT Pharmaceuticals has announced the addition of another candidate, HY-091, to its R&D pipeline, for the management of vulvar lichen sclerosus...
312 Views
AFT Pharmaceuticals - R&D pipeline strengthens with new candidate
AFT Pharmaceuticals has bolstered its R&D pipeline with the addition of a new product candidate, HY-090, a locally acting novel molecule,...
754 Views
AFT Pharmaceuticals - Global growth despite tough macro environment
AFT Pharmaceuticals reported solid H124 top-line growth, driven by strong momentum in the Asian and international markets. H124 revenues of...
432 Views
AFT Pharmaceuticals - 1H24 Result — Not Without Some Pain
The key positive was underlying non-ANZ sales growth of +95% versus 1H23, which, coupled with ongoing solid ANZ performance, more than offset gross...
489 Views
AFT Pharmaceuticals - FDA nod for opioid alternative, upside anticipated
AFT Pharmaceuticals announced FDA approval for Maxigesic IV, an intravenous form of its flagship pain relief prescription medicine. The FDA...
560 Views